Nippon Boehringer Ingelhemi to Solely Market Alesion Anti-allergic Agent.Tokyo, Japan, July 29, 2005 - (JCNN JCNN Japan Corporate News Network ) - Nippon Boehringer Ingelheim announced on July 28 that it has agreed with Sankyo on sales of Alesion. Specifically, Nippon Boehringer Ingelheim will solely market the agent beginning on September 28. Developed by Nippon Boehringer Ingelheim, Alesion is a once-daily, non-sedative anti-allergic agent prescribed for the treatment of bronchial asthma bronchial asthma n. A condition of the lungs characterized by widespread narrowing of the airways due to spasm of the smooth muscle, edema of the mucosa, and the presence of mucus in the lumen of the bronchi and bronchioles. (adult patients only), allergic rhinitis Allergic Rhinitis Definition Allergic rhinitis, more commonly referred to as hay fever, is an inflammation of the nasal passages caused by allergic reaction to airborne substances. , and allergic dermatitis. Since the launch in 1994, the two companies have collaborated in promoting the agent. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion